In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia

Medicine & Life Sciences

• tipifarnib 100%
• Farnesyltranstransferase 88%
• Primary Myelofibrosis 72%
• 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27%
• 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 27%
• In Vitro Techniques 25%
• Phosphatidylinositol 3-Kinase 23%
• Myeloid Progenitor Cells 15%
• Myeloproliferative Disorders 15%
• Mitogen-Activated Protein Kinase 1 13%
• Protein Kinase Inhibitors 12%
• Hematologic Neoplasms 11%
• Acute Myeloid Leukemia 11%
• Thrombocytopenia 10%
• Cell Proliferation 7%
• Peptides 7%
• Therapeutics 1%